Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.

Japanese journal of clinical oncology - 1 Jan 2021

Naito Tomoyuki, Shiraishi Hideaki, Fujiwara Yutaka

Abstract excerpt

Major issues in anaplastic lymphoma kinase-positive non-small cell lung carcinoma are acquired resistance against anaplastic lymphoma kinase inhibitors and control of central nervous system metastasis. The development of these inhibitors has changed therapeutic strategy in patients with advanced anaplastic lymphoma kinase-positive non-small cell lung carcinoma. Brigatinib and lorlatinib were designed to penetrate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Central Nervous System Neoplasms

Share to Crizotinib

Share to Lactams

Share to Lactams, Macrocyclic

Share to Organophosphorus Compounds

Share to Pyrazoles

Source

Identifiers

PMID: 33147606
DOI: 10.1093/jjco/hyaa192

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.PMID 33147606Read ↗

Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.Semantic proximity Read ↗

Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.Semantic proximity Read ↗

Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer.Semantic proximity Read ↗

Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.Semantic proximity Read ↗

The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to dateSemantic proximity Read ↗

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.Semantic proximity Read ↗

The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report.Semantic proximity Read ↗

Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.Semantic proximity Read ↗

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.Semantic proximity Read ↗

High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.